Latest News
Amgen Invests Additional USD 421m in BeiGene
Wednesday 15 July 2020

US biotech company Amgen (NASDAQ: AMGN) has invested an additional USD 421m in China-based biotechnology company BeiGene's registered direct offering of ordinary shares, maintaining Amgen's ownership of BeiGene at approximately 20.3%, the company said.

This additional investment reflects Amgen's confidence in the progress the companies are making in their ongoing oncology collaboration in China, the world's second largest pharmaceutical market.

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics.
Date Published: 15/07/2020